Daniel C. Javitt is 10% Owner at NRX Pharmaceuticals, Inc. (NRXP). They have made 3 open-market trades across 1 company since 2022, most recently 2022-11-30.
CIK 0001864534
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NRXP | 9,634,793 | $25.1M |
Shares reported on the most recent Form 4, priced at the 2022-12-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NRXP | SELL · 10b5-1 | 2022-11-29 | 2022-12-01 | $1.50 | $33K | -25.2% | -17.7% | -36.7% |
| NRXP | SELL | 2022-11-16 | 2022-11-18 | $1.02 | $307K | +29.8% | -6.1% | -5.3% |
| NRXP | SELL · 10b5-1 | 2022-11-11 | 2022-11-15 | $1.01 | $50K | +33.0% | +16.0% | +21.3% |
| NRXP | SELL | 2022-07-29 | 2022-08-02 | $1.01 | $1.6M | +19.3% | -0.8% | +20.9% |
| NRXP | SELL | 2022-06-03 | 2022-06-07 | $0.68 | $608K | -15.8% | -13.1% | +2.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.